Charles River Laboratories, a global preclinical CRO, has opened its new biomedical diagnostic testing facility in Wilmington, Mass.
The state-of-the-art, 60,000 square foot R&D services facility expands the company’s diagnostic capabilities for research model health monitoring, clinical chemistry, hematology, biomarker assay development and immunoassay services. The new facility offers high-functioning, controlled environments, building monitoring and mechanical systems redundancy, as well as energy reduction through occupancy sensor-driven air distribution and lighting.
“Our new facility provides Charles River with additional capacity for growth, as well as the capability to utilize innovative technology platforms to advance the high-quality R&D services we provide our biopharmaceutical and academic clients,” said James C. Foster, chairman, president and CEO, Charles River Laboratories.
Charles River is one of the largest global preclinical CROs, with approximately 1,000 employees in Massachusetts and approximately 7,100 employees globally.